SCHEMBL21875232

SCHEMBL21875232

NCCNc1nc2ccccc2c2c(=O)c3cc(F)ccc3sc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 2/20 0.38
GLA P06280 1/20 0.37
TOP2A P11388 2/20 0.37
TOP1 P11387 1/20 0.37
KDM4E B2RXH2 1/20 0.35
FERMT2 Q96AC1 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ILK Q13418 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
PKN2 Q16513 1/20 0.35
HDAC1 Q13547 3/20 0.35
APP P05067 2/20 0.34
HDAC3 O15379 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
MERTK Q12866 1/20 0.34
SYK P43405 1/20 0.34
TOP2B Q02880 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089850 1.00 PRKCI (0.38) PRKCIGLATOP2ATOP1KDM4E
SCHEMBL21450996 0.94 SYK (0.41) GLATOP2ATOP1L3MBTL1ROCK2
SCHEMBL30089846 0.94 SYK (0.41) GLATOP2ATOP1L3MBTL1ROCK2
SCHEMBL21451013 0.93 FERMT2 (0.37) PRKCIKDM4EFERMT2HDAC1LMNA
SCHEMBL21451072 0.90 KDM4E (0.42) GLATOP2ATOP1KDM4ELMNA
SCHEMBL21451071 0.90 MERTK (0.45) GLATOP2ATOP1KDM4EL3MBTL1
SCHEMBL30089833 0.89 GLA (0.36) GLATOP2ATOP1L3MBTL1HDAC1
SCHEMBL21875228 0.89 GLA (0.36) GLATOP2ATOP1L3MBTL1HDAC1
SCHEMBL21450995 0.88 RAD52 (0.42) KDM4EILKHDAC1HDAC3HDAC2
SCHEMBL21450925 0.88 KDM4E (0.40) PRKCITOP2ATOP1KDM4EILK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110945001-B FMS-like tyrosine kinase inhibitors 硕英生医股份有限公司 2022-11-25 CN claimed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 PRKCI 347/4885GLA 4234/4885TOP2A 2701/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 PRKCI 347/4885GLA 4234/4885TOP2A 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.